

Other indications for Sirolimus

Adults:

- *Renal angiomyolipoma (off-label use):* Oral: Initial: 0.5 mg/m² once daily titrated to a target trough level of 3 to 6 ng/mL (may increase to target trough level of 6 to 10 ng/mL if <10% reduction in lesion diameters at 2 months) for 2 years.
- *GVHD (Prevention):* 12 mg loading dose on day 3, followed by 4 mg daily (target trough level: 3 to 12 ng/mL); taper off after 6 to 9 months.
- *Treatment of refractory acute GVHD:* 4 to 5 mg/m² for 14 days (no loading dose).
- *Treatment of chronic GVHD:* 6 mg loading dose, followed by 2 mg daily (target trough level: 7 to 12 ng/mL) for 6 to 9 months.^{[1] [2]}

[1] - ntin J, Kim H, Cutler C, et al, "Sirolimus, Tacrolimus, and Low-Dose Methotrexate for Graft-Versus-Host Disease Prophylaxis in Mismatched Related Donor or Unrelated Donor Transplantation," Blood, 2003, 102(5):1601-5.[[PubMed 12730113](#)]

[2]- Armand P, Gannamaneni S, Kim HT, et al, "Improved Survival in Lymphoma Patients Receiving Sirolimus for Graft-Versus-Host Disease Prophylaxis After Allogeneic Hematopoietic Stem-Cell Transplantation With Reduced-Intensity Conditioning," J Clin Oncol, 2008, 26(35):5767-74.[[PubMed 19001324](#)]

